NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

TerrAscend Corp. (TSND.TO) Stock Analysis

TerrAscend Corp. (TSND.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

TSND.TO

CA$0.70

+CA$0.01 (+1.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TSND.TO with… →

TSND.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$0.68
Previous Close
CA$0.69
Day's Range
0.68–0.72
52-Week Range
0.53–2.00
Volume
93.17K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.17
Valuation
Market Cap
CA$260.87M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
99.52
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.15
Financials (FY)
Revenue (FY)
CA$260.56M−2.81%
Net Income (FY)
−CA$86.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
−15.72%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
309.18M
1-Year Return
−32.69%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
194.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TSND.TO closed at CA$0.70, −32.69% over 1 year.

TerrAscend Corp. (TSND.TO) has a market capitalization of CA$260.87M.

In fiscal 2025, TSND.TO reported revenue of CA$260.56M.

TSND.TO Stock Return by Calendar Year

TerrAscend Corp. (TSND.TO) return since May 2017: what CA$10,000 became

1 year
CA$10,000 CA$6,731
−32.69%
5 years
CA$10,000 CA$986
−90.14%
Since May 2017
CA$10,000 CA$5,785
−42.15%

If you had invested CA$10,000 in TerrAscend Corp. (TSND.TO) at the close on May 3, 2017, the earliest close on record here, it would have been worth CA$5,785 at the close on October 21, 2026: −42.15% in total, −5.62% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−29.29%
2025+7.61%
2024−58.18%
2023+41.94%
2022−80.05%
2021−38.82%
2020+347.18%
2019−51.20%
2018+92.08%
2017 (partial year)+150.41%

As of October 21, 2026.

TSND.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$260.56M−CA$86.23M−33.1%
2024CA$268.08M−CA$80.23M−29.9%
2023CA$250.51M−CA$95.54M−38.1%
2022CA$247.83M−CA$303.96M−122.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$260.56MCA$136.32MCA$44.63M−CA$86.23M−33.1%
2024CA$268.08MCA$135.87MCA$41.36M−CA$80.23M−29.9%
2023CA$250.51MCA$138.02MCA$49.97M−CA$95.54M−38.1%
2022CA$247.83MCA$101.50M−CA$3.97M−CA$303.96M−122.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TSND.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricTSND.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.992.1053% below
Profit margin−15.72%−8.14%7.6 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

TerrAscend Corp. (TSND.TO) carries a market capitalisation of CA$260.87M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 828 employees.

The most recent close on file for TSND.TO is CA$0.70, dated October 21, 2026. That is +CA$0.01 (+1.45%) against the previous close. Over the past 52 weeks the price has ranged from CA$0.53 to CA$2.00. The latest close sits 32.08% above that 52-week low.

Financial Health

In fiscal 2025, TerrAscend Corp. reported revenue of CA$260.56M. That is −2.81% against the prior fiscal year, when revenue was CA$268.08M. The same year closed with a net loss of CA$86.23M. Profit margin runs at −15.72%. That is 7.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.15.

Across the 4 fiscal years on file, revenue moves from CA$247.83M in 2022 to CA$260.56M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 99.52. Measured against sales, the shares trade at 0.99 times revenue. On price-to-sales that is 52.93% below the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 2.17. Annualized volatility over the trailing 9 years is 95.39%. Over the trailing twelve months the total return is −32.69%. Measured over 5 years, that is −37.08% a year compounded.

Growth & Income

The record shows no dividend for TSND.TO.

2026 is still running; the total return is −29.29% year to date. Across the complete calendar years on file, 2020 returned +347.18% and 2022 returned −80.05%. Of the 8 complete calendar years on file, 4 finished higher.

Peer Comparison

TerrAscend Corp. (TSND.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TerrAscend Corp. TSND.TO CA$260.87M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. TerrAscend Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About TerrAscend Corp.

TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, and Cookies. The company also operates retail dispensaries under the Apothecarium brand name. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

Visit website →